- Q4 2023 InflaRx NV Earnings Call TranscriptMar 21, 2024€1.43 (-9.51%)Earnings
- InflaRx NV Conference Call TranscriptJan 04, 2024
- InflaRx NV at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- InflaRx NV Corporate Call TranscriptSep 11, 2023
- InflaRx NV PANAMO Ph3 Results Call TranscriptMar 31, 2022
- InflaRx NV Virtual R&D Event TranscriptFeb 03, 2022
- InflaRx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Inflarx NV at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Inflarx NV Pyoderma Gangrenosum Cohort Three Top-Line Results Conference Call TranscriptOct 27, 2021
- Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 23, 2021
- Inflarx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Inflarx NV at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Inflarx NV Earnings Call TranscriptNov 07, 2019€2.44 (+1.67%)Earnings
- InflaRx N.V. - Special Call TranscriptJul 19, 2019
InflaRx NV Virtual R&D Event Transcript
Hello, thank you for joining us at our virtual R&D event, where we will discuss our Phase III program for vilobelimab, including our new primary endpoint called the modified HiSCR. A replay will also be available on our website following the live event.
Before I begin, I'd like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These beliefs are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for more details.
Today, our agenda will include an introduction by Niels, and HS disease overview presented by our special guest, Dr. Chris Sayed, review of vilobelimab and the mechanism of action, review of our Phase IIb SHINE study, along with key learnings. And finally, what we're all waiting for is our new Phase III program with the primary endpoint called modified HiSCR along with additional data post hoc from our SHINE study. We will also conclude the event
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)